Journal
FRONTIERS IN MEDICINE
Volume 5, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fmed.2018.00110
Keywords
cardiomyocyte; maturation; cell manufacturing; human pluripotent stem cells; coculture; cardiac repair; differentiation; regenerative medicine
Categories
Funding
- NIH [R01EB007534]
- NSF [1547225, 1743346, 1648035]
- NIH Chemistry Biology Interface Training Grand [NIGMS T32 GM008505]
- Directorate For Engineering
- Div Of Chem, Bioeng, Env, & Transp Sys [1547225, 1743346] Funding Source: National Science Foundation
Ask authors/readers for more resources
Recent advances in the differentiation and production of human pluripotent stem cell (hPSC)-derived cardiomyocytes (CMs) have stimulated development of strategies to use these cells in human cardiac regenerative therapies. A prerequisite for clinical trials and translational implementation of hPSC-derived CMs is the ability to manufacture safe and potent cells on the scale needed to replace cells lost during heart disease. Current differentiation protocols generate fetal-like CMs that exhibit proarrhythmogenic potential. Sufficient maturation of these hPSC-derived CMs has yet to be achieved to allow these cells to be used as a regenerative medicine therapy. Insights into the native cardiac environment during heart development may enable engineering of strategies that guide hPSC-derived CMs to mature. Specifically, considerations must be made in regard to developing methods to incorporate the native intercellular interactions and biomechanical cues into hPSC-derived CM production that are conducive to scale-up.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available